MedTrace Logo

[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes

NCT02967354 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2018-01-30

Study results available
· View outcomes & findings →

Summary

Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the \[11C\]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.

Conditions

  • Type2 Diabetes

Interventions

RADIATION

Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan

Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan

Sponsors & Collaborators

  • Per-Ola Carlsson

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-10-31
Completion
2015-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02967354 on ClinicalTrials.gov